Why the study?
Despite advances in the treatment of heart failure, mortality and morbidity remain high, prompting the development of novel medical and surgical strategies to reduce disease burden.
A review of the ESC 2023 congress highlights novel adjuvant treatments for heart failure that may influence future clinical guidelines.
Answers are grounded in this paper and cite their sources.
May prompt HF guideline revisions; extends ESC congress strategies into practice.
Context: Despite advances in the treatment of heart failure, mortality and morbidity remain high. Novel medical and surgical treatments have attempted to reduce the burden of disease. Evidence Acquisition: In this review, we discussed newly proposed strategies for the treatment of heart failure based on the recent European Society of Cardiology (ESC) congress. Results: Recent advances in heart failure treatment may play a pivotal role in prognosis and lead to significant changes in guideline-based recommendations. Conclusions: Recent trials have demonstrated the effectiveness of several adjuvant treatments for heart failure.
No takes yet. Share an insight, caveat, or question.
Sepideh Jafari Naeini (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: